JMP Securities Initiates Coverage on TorreyPines Therapeutics (TPTX) with a Strong Buy
More News related to TPTX
- StreetInsider.com Notable Analyst Rating Changes: 09/14
- JMP Securities Initiates Coverage on TorreyPines Therapeutics (TPTX) with a Strong Buy
- TorreyPines (TPTX) Completes Phase I Multiple Dose Clinical Trial of NGX267
- TorreyPines Therapeutics (TPTX) Initiates Phase I Multiple Dose Clinical Trial of Tezampanel
- RBC Capital Starts TorreyPines Therapeutics (TPTX) at Outperform
More News related to New Coverage
- Canaccord Adams Initiates Coverage on Swift Energy (SFY) with a Buy; Legacy Assets Providing a Launch Pad
- Canaccord Adams Initiates Coverage on Gastar Exploration (GST) with a Buy; Digging Deep for Returns
- Caris & Co Initiates Coverage on Medco Health Solutions (MHS) with an Above Average
- Brigantine Advisors Initiates Coverage on Align Technology (ALGN) with a Buy; Anticipate Strong Growth from Orthodontic Channel
- UBS Initiates Coverage on Trustmark (TRMK) with a Neutral
JMP Securities initiates coverage on TorreyPines Therapeutics (Nasdaq: TPTX) with a Strong Buy.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
